☰

Claudio E. Chuaqui - Publications

Affiliations: 
Celegene 
Area:
Pharma
Tree Info Similar researchers PubMed Report error

38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Su Q, Banks E, Bebernitz G, Bell K, Borenstein CF, Chen H, Chuaqui C, Deng N, Ferguson AD, Kawatkar SP, Grimster NP, Ruston L, Lyne P, Read JA, Peng XY, et al. Discovery of (2R)-N-[3-[2-[(3-methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a potent and selective Janus Kinase 1 (JAK1) inhibitor. Journal of Medicinal Chemistry. PMID 32297743 DOI: 10.1021/Acs.Jmedchem.9B01392  0.411
2019 Hu S, Marineau J, Hamman K, Bradley M, Savinainen A, Alnemy S, Rajagopal N, Orlando D, Chuaqui C, Olson E. Abstract 4421: SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo Cancer Research. 79: 4421-4421. DOI: 10.1158/1538-7445.Sabcs18-4421  0.346
2018 Grimster NP, Anderson E, Alimzhanov M, Bebernitz G, Bell K, Chuaqui C, Deegan T, Ferguson AD, Gero T, Harsch A, Huszar D, Kawatkar A, Kettle JG, Lyne PD, Read JA, et al. Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors. Journal of Medicinal Chemistry. PMID 29856615 DOI: 10.1021/Acs.Jmedchem.8B00076  0.428
2017 McCoull W, Abrams RD, Anderson E, Blades K, Barton P, Box M, Burgess J, Byth K, Cao Q, Chuaqui C, Carbajo RJ, Cheung T, Code E, Ferguson AD, Fillery S, et al. Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors. Journal of Medicinal Chemistry. PMID 28485934 DOI: 10.1021/Acs.Jmedchem.7B00359  0.389
2017 Kettle JG, Su Q, Grimster N, Kawatkar S, Throner S, Woessner R, Chen H, Bebernitz G, Bell K, Anderson E, Ruston L, Winter-Holt J, Lyne P, Vasbinder M, Chuaqui C. Abstract 979: Discovery of the JAK1 selective kinase inhibitor AZD4205 Cancer Research. 77: 979-979. DOI: 10.1158/1538-7445.Am2017-979  0.422
2016 McCoull W, Hennessy EJ, Blades K, Chuaqui C, Dowling JE, Ferguson AD, Goldberg FW, Howe N, Jones CR, Kemmitt PD, Lamont G, Varnes JG, Ward RA, Yang B. Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors. Acs Medicinal Chemistry Letters. 7: 1118-1123. PMID 27994749 DOI: 10.1021/Acsmedchemlett.6B00322  0.428
2016 Akçay G, Belmonte MA, Aquila B, Chuaqui C, Hird AW, Lamb ML, Rawlins PB, Su N, Tentarelli S, Grimster NP, Su Q. Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain. Nature Chemical Biology. PMID 27595327 DOI: 10.1038/Nchembio.2174  0.341
2016 Hennessy EJ, Chuaqui C, Ashton S, Colclough N, Cross DA, Debreczeni JÉ, Eberlein C, Gingipalli L, Klinowska TC, Orme JP, Sha L, Wu X. Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation. Acs Medicinal Chemistry Letters. 7: 514-519. PMID 27190603 DOI: 10.1021/Acsmedchemlett.6B00058  0.372
2016 Dowling JE, Alimzhanov M, Bao L, Chuaqui C, Denz CR, Jenkins E, Larsen NA, Lyne PD, Pontz T, Ye Q, Holdgate GA, Snow L, O'Connell N, Ferguson AD. Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo. Acs Medicinal Chemistry Letters. 7: 300-5. PMID 26985319 DOI: 10.1021/Acsmedchemlett.5B00452  0.361
2015 Vasbinder MM, Alimzhanov M, Augustin M, Bebernitz G, Bell K, Chuaqui C, Deegan T, Ferguson AD, Goodwin K, Huszar D, Kawatkar A, Kawatkar S, Read J, Shi J, Steinbacher S, et al. Identification of azabenzimidazoles as potent JAK1 selective inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 26614408 DOI: 10.1016/J.Bmcl.2015.11.031  0.376
2014 Yang B, Lamb ML, Zhang T, Hennessy EJ, Grewal G, Sha L, Zambrowski M, Block MH, Dowling JE, Su N, Wu J, Deegan T, Mikule K, Wang W, Kaspera R, ... Chuaqui C, et al. Discovery of potent KIFC1 inhibitors using a method of integrated high-throughput synthesis and screening. Journal of Medicinal Chemistry. 57: 9958-70. PMID 25458601 DOI: 10.1021/Jm501179R  0.392
2014 Johannes JW, Chuaqui C, Cowen S, Devereaux E, Gingipalli L, Molina A, Wang T, Whitston D, Wu X, Zhang HJ, Zinda M. Discovery of 6-aryl-azabenzimidazoles that inhibit the TBK1/IKK-ε kinases. Bioorganic & Medicinal Chemistry Letters. 24: 1138-43. PMID 24462666 DOI: 10.1016/J.Bmcl.2013.12.123  0.433
2014 Su Q, Ioannidis S, Chuaqui C, Almeida L, Alimzhanov M, Bebernitz G, Bell K, Block M, Howard T, Huang S, Huszar D, Read JA, Rivard Costa C, Shi J, Su M, et al. Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. Journal of Medicinal Chemistry. 57: 144-58. PMID 24359159 DOI: 10.1021/Jm401546N  0.377
2014 McCoull W, Hennessy EJ, Blades K, Box MR, Chuaqui C, Dowling JE, Davies CD, Ferguson AD, Goldberg FW, Howe NJ, Kemmitt PD, Lamont GM, Madden K, McWhirter C, Varnes JG, et al. Identification and optimisation of 7-azaindole PAK1 inhibitors with improved potency and kinase selectivity Medchemcomm. 5: 1533-1539. DOI: 10.1039/C4Md00280F  0.43
2013 Dowling JE, Alimzhanov M, Bao L, Block MH, Chuaqui C, Cooke EL, Denz CR, Hird A, Huang S, Larsen NA, Peng B, Pontz TW, Rivard-Costa C, Saeh JC, Thakur K, et al. Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. Acs Medicinal Chemistry Letters. 4: 800-5. PMID 24900749 DOI: 10.1021/Ml400197U  0.388
2013 Ward RA, Anderton MJ, Ashton S, Bethel PA, Box M, Butterworth S, Colclough N, Chorley CG, Chuaqui C, Cross DA, Dakin LA, Debreczeni JÉ, Eberlein C, Finlay MR, Hill GB, et al. Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). Journal of Medicinal Chemistry. 56: 7025-48. PMID 23930994 DOI: 10.1021/Jm400822Z  0.387
2013 Wu J, Mikule K, Wang W, Su N, Petteruti P, Gharahdaghi F, Code E, Zhu X, Jacques K, Lai Z, Yang B, Lamb ML, Chuaqui C, Keen N, Chen H. Discovery and mechanistic study of a small molecule inhibitor for motor protein KIFC1. Acs Chemical Biology. 8: 2201-8. PMID 23895133 DOI: 10.1021/Cb400186W  0.303
2013 Woessner R, Bebernitz G, Bell K, Caccese R, Johnson N, Kettle J, Rivard C, Schroeder P, Su Q, Wang H, Ye M, Zheng W, Zinda M, Lyne P, Vasbinder M, ... ... Chuaqui C, et al. Abstract 931: Highly selective JAK1 kinase inhibitors suppress Y705-mediated STAT3 activation in a wide range of tumor types, with reduced hematological toxicity. Cancer Research. 73: 931-931. DOI: 10.1158/1538-7445.Am2013-931  0.384
2013 Lamb ML, Wu J, Mikule K, Wang W, Su N, Petteruti P, Gharahdaghi F, Code E, Zhu X, Jacques K, Lai Z, Zhang T, Boulay D, Grewal G, Keen N, ... ... Chuaqui C, et al. Abstract C55: Discovery and optimization of inhibitors of the KIFC1 motor protein. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C55  0.334
2013 Finlay MRV, Anderton M, Ashton S, Ballard PG, Bradbury RH, Butterworth S, Chuaqui CE, Colclough N, Cross DAE, McFarland HL, Mellor MJ, Ward RA, Waring MJ. Abstract B94: Discovery of and first disclosure of the clinical candidate AZD9291, a potent and selective third-generation EGFR inhibitor of both activating and T790M resistant mutations that spares the wild type form of the receptor. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B94  0.366
2012 Dowling JE, Chuaqui C, Pontz TW, Lyne PD, Larsen NA, Block MH, Chen H, Su N, Wu A, Russell D, Pollard H, Lee JW, Peng B, Thakur K, Ye Q, et al. Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization. Acs Medicinal Chemistry Letters. 3: 278-83. PMID 24900464 DOI: 10.1021/Ml200257N  0.427
2012 Wang T, Block MA, Cowen S, Davies AM, Devereaux E, Gingipalli L, Johannes J, Larsen NA, Su Q, Tucker JA, Whitston D, Wu J, Zhang HJ, Zinda M, Chuaqui C. Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases. Bioorganic & Medicinal Chemistry Letters. 22: 2063-9. PMID 22305584 DOI: 10.1016/J.Bmcl.2012.01.018  0.405
2010 Guckian K, Carter MB, Lin EY, Choi M, Sun L, Boriack-Sjodin PA, Chuaqui C, Lane B, Cheung K, Ling L, Lee WC. Pyrazolone based TGFbetaR1 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 20: 326-9. PMID 19914068 DOI: 10.1016/J.Bmcl.2009.10.108  0.376
2009 Nandigam RK, Kim S, Singh J, Chuaqui C. Position specific interaction dependent scoring technique for virtual screening based on weighted protein--ligand interaction fingerprint profiles. Journal of Chemical Information and Modeling. 49: 1185-92. PMID 19415918 DOI: 10.1021/Ci800466N  0.301
2009 Bonafoux D, Chuaqui C, Boriack-Sjodin PA, Fitch C, Hankins G, Josiah S, Black C, Hetu G, Ling L, Lee W. 2-Aminoimidazoles inhibitors of TGF-beta receptor 1. Bioorganic & Medicinal Chemistry Letters. 19: 912-916. PMID 19135364 DOI: 10.1016/J.Bmcl.2008.11.119  0.311
2008 Fu K, Corbley MJ, Sun L, Friedman JE, Shan F, Papadatos JL, Costa D, Lutterodt F, Sweigard H, Bowes S, Choi M, Boriack-Sjodin PA, Arduini RM, Sun D, Newman MN, ... ... Chuaqui CE, et al. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arteriosclerosis, Thrombosis, and Vascular Biology. 28: 665-71. PMID 18202322 DOI: 10.1161/Atvbaha.107.158030  0.322
2006 Sun D, Chuaqui C, Deng Z, Bowes S, Chin D, Singh J, Cullen P, Hankins G, Lee WC, Donnelly J, Friedman J, Josiah S. A kinase-focused compound collection: compilation and screening strategy. Chemical Biology & Drug Design. 67: 385-94. PMID 16882313 DOI: 10.1111/J.1747-0285.2006.00396.X  0.382
2006 Singh J, Deng Z, Narale G, Chuaqui C. Structural Interaction Fingerprints: A New Approach to Organizing, Mining, Analyzing, and Designing Protein–Small Molecule Complexes Chemical Biology & Drug Design. 67: 5-12. PMID 16492144 DOI: 10.1111/J.1747-0285.2005.00323.X  0.331
2006 Deng Z, Chuaqui C, Singh J. Knowledge-based design of target-focused libraries using protein-ligand interaction constraints. Journal of Medicinal Chemistry. 49: 490-500. PMID 16420036 DOI: 10.1021/Jm050381X  0.342
2005 Chuaqui C, Deng Z, Singh J. Interaction Profiles of Protein Kinase−Inhibitor Complexes and Their Application to Virtual Screening Journal of Medicinal Chemistry. 48: 121-133. PMID 15634006 DOI: 10.1021/Jm049312T  0.396
2004 Chin DN, Chuaqui CE, Singh J. Integration of virtual screening into the drug discovery process Mini-Reviews in Medicinal Chemistry. 4: 1053-1065. PMID 15579113 DOI: 10.2174/1389557043403044  0.32
2004 Singh J, Chuaqui C, Annboriacksjodin P, Lee W, Pontz T, Corbley M, Cheung H, Arduini R, Mead J, Newman M. Corrigendum to “Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)”: [Bioorg. Med. Chem. Lett. 13 (2003) 4355] Bioorganic & Medicinal Chemistry Letters. 14: 2991. DOI: 10.1016/S0960-894X(04)00379-8  0.38
2004 Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee W, Pontz T, Corbley MJ, Cheung H-, Arduini RM, Mead JN, Newman MN, Papadatos JL, Bowes S, Josiah S, Ling LE. Corrigendum to “Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)” Bioorganic & Medicinal Chemistry Letters. 14: 2991. DOI: 10.1016/J.Bmcl.2004.03.027  0.358
2003 Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, Corbley MJ, Cheung HK, Arduini RM, Mead JN, Newman MN, Papadatos JL, Bowes S, Josiah S, Ling LE. Successful shape-Based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI) Bioorganic and Medicinal Chemistry Letters. 13: 4355-4359. PMID 14643325 DOI: 10.1016/J.Bmcl.2003.09.028  0.425
1996 Thachuk M, Chuaqui CE, Le Roy RJ. Linewidths and shifts of very low temperature CO in He: A challenge for theory or experiment? Journal of Chemical Physics. 105: 4005-4014. DOI: 10.1063/1.472274  0.546
1996 Bissonnette C, Chuaqui CE, Crowell KG, Le Roy RJ, Wheatley RJ, Meath WJ. A reliable new potential energy surface for H2-Ar Journal of Chemical Physics. 105: 2639-2653. DOI: 10.1063/1.472127  0.571
1994 Chuaqui CE, Le Roy RJ, McKellar ARW. Infrared spectrum and potential energy surface of He-CO The Journal of Chemical Physics. 101: 39-61. DOI: 10.1063/1.468147  0.581
1992 Slee T, Le Roy RJ, Chuaqui CE. Calculated rovibrational energy levels and infrared spectrum of he–c2h2 Molecular Physics. 77: 111-134. DOI: 10.1080/00268979200102341  0.564
Show low-probability matches.